Evidence map›Paper›PMID 31743358›Full record

ArticlePloS one2019

Determinants of mortality among patients with drug-resistant tuberculosis in northern Nigeria.

Mamman Bajehson, Baba Maiyaki Musa, Mustapha Gidado, Bassey Nsa, Useni Sani, Ahmad T Habibu, Ibrahim Aliyu, Tijjani Hussaini, AbdulRasheed Yusuf, Yakubu Gida

Abstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mamman BajehsonKNCV/Challenge TB, Kano Regional Office, Kano, Nigeria.ORCID 0000-0002-5499-5635
Baba Maiyaki MusaDepartment of Medicine, Bayero University, Kano, Nigeria.
Mustapha GidadoKNCV Tuberculosis Foundation, The Hague, Netherlands.
Bassey NsaKNCV Nigeria/ Challenge TB, Country Office, Abuja, Nigeria.
Useni SaniKNCV Nigeria/ Challenge TB, Country Office, Abuja, Nigeria.
Ahmad T HabibuKNCV/Challenge TB, Kano Regional Office, Kano, Nigeria.
Ibrahim AliyuKano State Tuberculosis and Leprosy Control Program, Kano, Nigeria.
Tijjani HussainiState Ministry of Health, Kano, Nigeria.
AbdulRasheed YusufKatsina State Tuberculosis and Leprosy Control Program, Katsina, Nigeria.
Yakubu GidaBauchi State Tuberculosis and Leprosy Control Program, Bauchi, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDrug-Resistant tuberculosis (DR-TB) is estimated to cause about 10% of all TB related deaths. There is dearth of data on determinants of DR-TB mortality in Nigeria. Death among DR-TB treated cohorts in Nigeria from 2010 to 2013 was 30%, 29%, 15% and 13% respectively. Our objective was to identify factors affecting survival among DR-TB patients in northern Nigeria.

methodsDemographic and clinical data of all DR-TB patients enrolled in Kano, Katsina and Bauchi states of Nigeria between 1st February 2015 and 30th November 2016 was used. Survival analysis was done using Kaplan-Meier and multiple regression with Cox proportional hazard modeling.

resultsMean time to death during treatment is 19.2 weeks and 3.9 weeks among those awaiting treatment. Death was recorded among 38 of the 147 DR-TB patients assessed. HIV co-infection significantly increased probability of mortality, with an adjusted hazard ratio (aHR) of 2.35, 95% CI: 1.05-5.29, p = 0.038. Treatment delay showed significant negative association with survival (p = 0.000), not starting treatment significantly reduced probability of survival with an aHR of 7.98, 95% CI: 2.83-22.51, p = 0.000. Adjusted hazard ratios for patients started on treatment more than eight weeks after detection or within two to four weeks after detection, was beneficial though not statistically significant with respective p-values of 0.056 and 0.092. The model of care (facility vs. community-based) did not significantly influence survival.

conclusionBoth HIV co-infected DR-TB patients and DR-TB patients that fail to start treatment immediately after diagnosis are at significant risk of mortality. Our study showed no significant difference in mortality based on models of care. The study highlights the need to address programmatic and operational issues pertaining to treatment delays and strengthening DR-TB/HIV co-management as key strategies to reduce mortality.

Indexed as

AdolescentAdultAgedAged, 80 and overAntitubercular AgentsChildCross-Sectional StudiesFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMycobacterium tuberculosisNigeriaProportional Hazards ModelsTuberculosis, Multidrug-ResistantAntitubercular Agents

Identifiers

PMID31743358
PMCPMC6863558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.